You are here
INVOKANA® monotherapy demonstrated significantly greater reductions in body weight vs placebo at 26 weeks1,2
Secondary Endpoint: Adjusted Mean Change in Body Weight From Baseline at 26 Weeks (%)
INVOKANA® is not indicated for weight loss.
The efficacy and safety of INVOKANA® monotherapy were assessed in subjects with type 2 diabetes mellitus who were inadequately controlled with diet and exercise. In this 26-week, double-blind, placebo-controlled study, 584 patients were randomized to receive placebo (n=192), INVOKANA® 100 mg (n=195), or INVOKANA® 300 mg (n=197). Mean baseline A1C values were, respectively, 7.97%, 8.06%, and 8.01%. The primary endpoint was the change in A1C from baseline to week 26. Prespecified secondary endpoints included change in fasting plasma glucose, change in percent body weight, and change in systolic blood pressure.1,2
Learn about SYSTOLIC BLOOD PRESSURE CHANGE